The Priority Review

Tag

Stream

353 stories · page 17 of 30

Stories

  1. Clinical trials

    Mitapivat shows haemoglobin response in sickle cell disease trial

    In the RISE UP phase 3 trial, 56 (41%) of 138 patients on mitapivat achieved a haemoglobin response versus 2 (3%) of 69 on placebo, an adjusted difference of 38% (95% CI 29-47). The annualised rate of pain crises was 2·6 for mitapivat and 3·1 for placebo (p=0·1213).

  2. Clinical trials

    Nivolumab plus relatlimab plus chemo vs nivolumab plus chemo in NSCLC

    The authors reported that the primary endpoint of objective response rate was not met (51.3% versus 45.0%). In the PD-L1 ≥1% nonsquamous subgroup, a trend toward improved clinical benefit was seen (ORR 58.0% versus 39.6%; PFS HR 0.68).

  3. Clinical trials

    Lilly reports 79% response rate for Sofe-M in platinum-sensitive ovarian cancer

    The Phase 1 study of sofetabart mipitecan (Sofe-M) plus bevacizumab in 29 patients with measurable disease reported a confirmed objective response rate of 79.3% (23/29) and a disease control rate of 100%. The most common grade ≥3 adverse events were neutropenia (42%) and anemia (24%), with 6% of patients discontinuing treatment due to an adverse event.

  4. Regulation

    FDA issues priority review voucher for ISEMBYLD (apitegromab-mstn)

    The FDA announced the issuance of a priority review voucher to the sponsor of ISEMBYLD (apitegromab-mstn), approved September 11, 2026. The voucher is awarded because the product meets the criteria for rare pediatric disease applications under the FD&C Act.

  5. Approvals

    FDA approves first once-weekly insulin for type 2 diabetes in pediatric patients

    Awiqli (insulin icodec-abae) is approved for children aged 10 years and older with type 2 diabetes mellitus. The drug is administered by subcutaneous injection once weekly and was approved after a priority review.

  6. Policy

    CMS proposes pre-eligibility verification rule for health exchanges

    The rule would require exchanges to verify household income, family size, citizenship status and residence before providing financial assistance, with the first pre-Open-Enrollment verification window beginning August 1, 2027 for 2028 coverage. Stakeholders may submit comments during the 30-day period following publication.

  7. Policy

    UCB establishes Emmanuel Janssen Endowed Chair at Brigham and Women's Hospital

    UCB announced the creation of a permanently endowed chair in pharmacoepidemiology and pharmacoeconomics at Brigham and Women's Hospital, naming Sebastian Schneeweiss, MD, ScD, as the inaugural incumbent. The chair is intended to advance real-world evidence research and improve how medicines are evaluated and used in clinical practice.

  8. Policy

    CMS launches $275 million initiative to recruit nurses in nursing homes

    The initiative, funded by CMS and states, is expected to support more than 4,000 nurses and nursing students nationwide, offering up to $40,000 in student loan repayment or a $10,000 stipend for a three-year commitment in rural or higher labor-shortage areas. CMS has committed $100 million, with states committing at least an additional $175 million.

  9. Regulation

    AMA and EMA issue joint guidance on Ebola vaccine development

    The EMA's Emergency Task Force and the African Medicines Agency released a joint position paper outlining minimum requirements for clinical trials of Bundibugyo virus vaccines, including guidance on when animal toxicity studies may be waived. The paper also recommends early trials in Africa, a single-dose vaccine preference, and a ring trial design for Phase III studies.

  10. Regulation

    FDA corrects patent extension review periods for six drugs

    The FDA corrects the length of the regulatory review period for ANDEMBRY, ANZUPGO, ANKTIVA, BIZENGRI, BRINSUPRI, and DAYVIGO due to calculation errors. The corrections apply to determinations announced on August 10, August 17, and September 9, 2026; no other changes are made.

  11. Regulation

    FDA releases draft chapter on chemical hazard control for human food

    The FDA announced the availability of a new draft chapter, Chapter 12: Control of Chemical Hazards, as part of its multichapter draft guidance on Hazard Analysis and Risk-Based Preventive Controls for Human Food. The guidance is not final and is not yet in effect.

  12. Regulation

    FDA proposes action levels for cadmium in food for babies and young children

    The FDA announced a draft guidance titled "Action Levels for Cadmium in Processed Food Intended for Babies and Young Children" that will establish action levels for cadmium in certain processed foods intended for babies and young children less than 2 years old. The draft guidance is intended to set achievable action levels that will help further reduce cadmium in the food supply.